Silverfin false false 31/12/2025 01/01/2025 31/12/2025 Sakura Holloway 01/06/2025 Yves Le Goff 03/07/2021 Sandy Blackadder Primrose 17/10/2025 15/09/2021 Dr Andrew Mark Shaw 18/12/2008 Dr Jonathan Gregory Clifford Snicker 09/01/2026 01/04/2023 11 February 2026 The principal activity of the company in the year under review was that of the development and supply of blood testing devices. 06550714 2025-12-31 06550714 bus:Director1 2025-12-31 06550714 bus:Director2 2025-12-31 06550714 bus:Director3 2025-12-31 06550714 bus:Director4 2025-12-31 06550714 bus:Director5 2025-12-31 06550714 2024-12-31 06550714 core:CurrentFinancialInstruments 2025-12-31 06550714 core:CurrentFinancialInstruments 2024-12-31 06550714 core:Non-currentFinancialInstruments 2025-12-31 06550714 core:Non-currentFinancialInstruments 2024-12-31 06550714 core:ShareCapital 2025-12-31 06550714 core:ShareCapital 2024-12-31 06550714 core:SharePremium 2025-12-31 06550714 core:SharePremium 2024-12-31 06550714 core:RetainedEarningsAccumulatedLosses 2025-12-31 06550714 core:RetainedEarningsAccumulatedLosses 2024-12-31 06550714 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 06550714 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-12-31 06550714 core:LeaseholdImprovements 2024-12-31 06550714 core:PlantMachinery 2024-12-31 06550714 core:FurnitureFittings 2024-12-31 06550714 core:ComputerEquipment 2024-12-31 06550714 core:LeaseholdImprovements 2025-12-31 06550714 core:PlantMachinery 2025-12-31 06550714 core:FurnitureFittings 2025-12-31 06550714 core:ComputerEquipment 2025-12-31 06550714 core:FurtherRelatedPartyRelationshipType2ComponentAllOtherRelatedParties core:Non-currentFinancialInstruments 2025-12-31 06550714 core:FurtherRelatedPartyRelationshipType2ComponentAllOtherRelatedParties core:Non-currentFinancialInstruments 2024-12-31 06550714 bus:OrdinaryShareClass1 2025-12-31 06550714 bus:OrdinaryShareClass2 2025-12-31 06550714 2025-01-01 2025-12-31 06550714 bus:FilletedAccounts 2025-01-01 2025-12-31 06550714 bus:SmallEntities 2025-01-01 2025-12-31 06550714 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06550714 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06550714 bus:Director1 2025-01-01 2025-12-31 06550714 bus:Director2 2025-01-01 2025-12-31 06550714 bus:Director3 2025-01-01 2025-12-31 06550714 bus:Director4 2025-01-01 2025-12-31 06550714 bus:Director5 2025-01-01 2025-12-31 06550714 core:DevelopmentCostsCapitalisedDevelopmentExpenditure core:TopRangeValue 2025-01-01 2025-12-31 06550714 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-01-01 2025-12-31 06550714 core:PlantMachinery core:TopRangeValue 2025-01-01 2025-12-31 06550714 core:FurnitureFittings 2025-01-01 2025-12-31 06550714 core:ComputerEquipment core:TopRangeValue 2025-01-01 2025-12-31 06550714 2024-01-01 2024-12-31 06550714 core:LeaseholdImprovements 2025-01-01 2025-12-31 06550714 core:PlantMachinery 2025-01-01 2025-12-31 06550714 core:ComputerEquipment 2025-01-01 2025-12-31 06550714 core:Non-currentFinancialInstruments 2025-01-01 2025-12-31 06550714 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 06550714 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 06550714 bus:OrdinaryShareClass2 2025-01-01 2025-12-31 06550714 bus:OrdinaryShareClass2 2024-01-01 2024-12-31 06550714 1 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 06550714 (England and Wales)

# ATTOMARKER LIMITED

### Unaudited Financial Statements
For the financial year ended 31 December 2025
Pages for filing with the registrar

ATTOMARKER LIMITED

## Unaudited Financial Statements

For the financial year ended 31 December 2025

Contents

ATTOMARKER LIMITED

## STATEMENT OF FINANCIAL POSITION

As at 31 December 2025
ATTOMARKER LIMITED

## STATEMENT OF FINANCIAL POSITION (continued)

As at 31 December 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  |  |  |
Intangible assets | 3 | 7,799,555 |  | 6,906,677
Tangible assets | 4 | 38,170 |  | 39,362
|  | 7,837,725 |  | 6,946,039
Current assets |  |  |  |
Stocks |  | 167,117 |  | 129,148
Debtors | 5 | 190,351 |  | 230,612
Cash at bank and in hand |  | 171,936 |  | 285,310
|  | 529,404 |  | 645,070
Creditors: amounts falling due within one year | 6 | ( 3,114,403) |  | ( 4,101,928)
Net current liabilities |  | (2,584,999) |  | (3,456,858)
Total assets less current liabilities |  | 5,252,726 |  | 3,489,181
Creditors: amounts falling due after more than one year | 7 | ( 563,431) |  | ( 419,977)
Net assets |  | 4,689,295 |  | 3,069,204
Capital and reserves |  |  |  |
Called-up share capital | 8 | 69 |  | 65
Share premium account |  | 4,574,199 |  | 3,410,234
Profit and loss account |  | 115,027 |  | ( 341,095 )
Total shareholders' funds |  | 4,689,295 |  | 3,069,204

For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Attomarker Limited (registered number: 06550714) were approved and authorised for issue by the Board of Directors on 11 February 2026. They were signed on its behalf by:

Dr Andrew Mark Shaw Director |

ATTOMARKER LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
ATTOMARKER LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Attomarker Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 1a Lamarr Building 3 Babbage Way, Exeter Science Park, Exeter, EX5 2FN, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. Following the conversion of the loan notes to Share capital post year end (as disclosed in note 11), the current liabilities position has improved significantly and therefore the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.
Exchange differences are recognised in the Statement of Income and Retained Earnings in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

##### Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Statement of Income and Retained Earnings in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Statement of Financial Position.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

##### Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Upon completion of the project, amortisation is to be charged on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Development costs | 5 years straight line

###### Research and development

Research expenditure is written off as incurred. Development expenditure is also written off, except where the directors are satisfied as to the technical, commercial and financial viability of individual projects. In such cases, the identifiable expenditure is capitalised as an intangible asset and amortised over the period during which the Company is expected to benefit. This period is between three and five years. Provision is made for any impairment.

##### Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line/reducing balance basis over its expected useful life, as follows:

Leasehold improvements | depreciated over the life of the lease
Plant and machinery | 4 years straight line
Fixtures and fittings | 15 % reducing balance
Computer equipment | 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

##### Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Statement of Income and Retained Earnings over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

##### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

##### Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

Convertible loan notes
The component parts of compound instruments issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. On initial recognition, the financial liability component is recorded at its fair value. At the date of issue, in the case of a convertible bond denominated in the functional currency of the issuer that may be converted into a fixed number of equity shares, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in the equity reserve within equity and is not subsequently remeasured.
Transaction costs are apportioned between the liability and equity components of the convertible instrument based on their relative fair values at the date of issue. The portion relating to the equity component is charged directly against equity.

##### Government grants

Government grants are recognised based on the performance model and are measured at the fair value of the asset received or receivable when there is reasonable assurance that the company will comply with conditions attaching to them and the grants will be received.
A grant that specifies performance conditions is recognised in income only when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the grant proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

##### Ordinary share capital

The ordinary share capital of the Company is presented as equity.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including directors | 15 |  | 11

#### 3. Intangible assets

| Development costs |  | Total
| £ |  | £
Cost |  |  |
At 01 January 2025 | 6,906,677 |  | 6,906,677
Additions | 892,878 |  | 892,878
At 31 December 2025 | 7,799,555 |  | 7,799,555
Accumulated amortisation |  |  |
At 01 January 2025 | 0 |  | 0
At 31 December 2025 | 0 |  | 0
Net book value |  |  |
At 31 December 2025 | 7,799,555 |  | 7,799,555
At 31 December 2024 | 6,906,677 |  | 6,906,677

#### 4. Tangible assets

| Leasehold improve- ments |  | Plant and machinery |  | Fixtures and fittings |  | Computer equipment |  | Total
| £ |  | £ |  | £ |  | £ |  | £
Cost |  |  |  |  |  |  |  |  |
At 01 January 2025 | 32,235 |  | 124,873 |  | 7,656 |  | 16,642 |  | 181,406
Additions | 5,320 |  | 431 |  | 4,187 |  | 3,158 |  | 13,096
Disposals | 0 |  | ( 948) |  | 0 |  | 0 |  | ( 948)
At 31 December 2025 | 37,555 |  | 124,356 |  | 11,843 |  | 19,800 |  | 193,554
Accumulated depreciation |  |  |  |  |  |  |  |  |
At 01 January 2025 | 13,443 |  | 114,088 |  | 2,239 |  | 12,274 |  | 142,044
Charge for the financial year | 4,796 |  | 4,714 |  | 1,257 |  | 2,803 |  | 13,570
Disposals | 0 |  | ( 230) |  | 0 |  | 0 |  | ( 230)
At 31 December 2025 | 18,239 |  | 118,572 |  | 3,496 |  | 15,077 |  | 155,384
Net book value |  |  |  |  |  |  |  |  |
At 31 December 2025 | 19,316 |  | 5,784 |  | 8,347 |  | 4,723 |  | 38,170
At 31 December 2024 | 18,792 |  | 10,785 |  | 5,417 |  | 4,368 |  | 39,362

#### 5. Debtors

| 2025 |  | 2024
| £ |  | £
Trade debtors | 776 |  | 10,579
Prepayments and accrued income | 7,875 |  | 15,465
VAT recoverable | 5,827 |  | 0
Other debtors | 175,873 |  | 204,568
| 190,351 |  | 230,612

#### 6. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Trade creditors | 78,221 |  | 97,180
Convertible loan notes | 2,230,396 |  | 3,258,085
Other loans | 649,866 |  | 624,866
Accruals and deferred income | 147,990 |  | 115,236
Other taxation and social security | 7,019 |  | 5,768
Other creditors | 911 |  | 793
| 3,114,403 |  | 4,101,928

#### 7. Creditors: amounts falling due after more than one year

| 2025 |  | 2024
| £ |  | £
Amounts owed to connected companies | 563,431 |  | 419,977

These amounts are unsecured and on which no interest is charged.

#### 8. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
6,182 Ordinary shares of £ 0.01 each (2024: 5,759 shares of £ 0.01 each) | 61.82 |  | 57.59
688 Deferred ordinary shares of £ 0.01 each | 6.88 |  | 6.88
| 68.70 |  | 64.47

During the financial year, 423 Ordinary shares of £0.01 each were issued with a total consideration of £1,163,969.

#### 9. Financial commitments

Commitments

| 2025 |  | 2024
| £ |  | £
Total future minimum lease payments under non-cancellable operating leases | 117,618 |  | 157,856

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as above.

Pensions

The Company operates a defined contribution pension scheme for the directors and employees. The assets of the scheme are held separately from those of the Company in an independently administered fund.

| 2025 |  | 2024
| £ |  | £
Unpaid contributions due to the fund (inc. in other creditors) | 911 |  | 793

#### 10. Related party transactions

Transactions with owners holding a participating interest in the entity

| 2025 |  | 2024
| £ |  | £
University of Exeter | 61,790 |  | 74,148

Other related party transactions

During the year the company had transactions with the following companies, in which at least one current or previous Director has an interest in, and they all relate to consultancy fees:
Cimelium Consulting Limited £95,255 (2024: £80,000).
Consultant Hub Ltd £105,490 (2024: £111,650).
The company also had transactions with Directors, that related to consultancy fees, which totalled £Nil (2024: £71,400) during the year.

#### 11. Events after the Balance Sheet date

On 9 January 2026, the company issued 1,131 Ordinary shares of £0.01 each in respect of the convertible loan notes with a total consideration of £2,230,396.